antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2025-71-1-2-56-63VPUVKBantibiotics-1330Research ArticleОБЗОРЫREVIEWSБезопасность, иммуногенность и клиническая эффективность пневмококковых конъюгированных вакцин у больных иммуновоспалительными ревматическими заболеваниямиSafety, Immunogenicity, and Clinical Efficacy of Pneumococcal Conjugate Vaccines in Patients with Autoimmune Inflammatory Rheumatic Diseaseshttps://orcid.org/0000-0003-4327-6720МуравьеваН. В.MuravyevaN. V.

Муравьева Наталья Валерьевна — к. м. н., старший научный сотрудник лаборатории коморбидных инфекций и вакцинопрофилактики

Москва

Researcher ID: AAF-4853-2021

Scopus Author ID: 57210263706

Natalia V. Muravyeva — Ph. D. in Medicine, Senior Researcher at the Laboratory of Comorbid Infections and Vaccine Prevention

Moscow

Researcher ID: AAF-4853-2021

Scopus Author ID: 57210263706

n-muravjeva@mail.ruhttps://orcid.org/0000-0002-5264-337XБарановаМ. М.BaranovaM. M.

Баранова Марина Михайловна — к. м. н., младший научный сотрудник лаборатории коморбиных инфекций и вакцинопрофилактики

Москва

Researcher ID: JDD-0658-2023

Scopus Author ID: 57222430929

Marina M. Baranova — Ph. D. in Medicine, Junior Researcher at the Laboratory of Comorbid Infections and Vaccine Prevention

Moscow

Researcher ID: JDD-0658-2023

Scopus Author ID: 57222430929

https://orcid.org/0000-0001-7091-2054Белов Б. С.BelovB. S.

Белов Борис Сергеевич — д. м. н., заведующий лабораторией коморбидных инфекций и вакцинопрофилактики

Москва

Researcher ID: ABD-2219-2020

Scopus Author ID: 7004592537

Boris S. Belov — D. Sc. in Medicine, Head of the Laboratory of Comorbid Infections and Vaccine Prevention

Moscow

Researcher ID: ABD-22192020

Scopus Author ID: 7004592537

ФГБНУ «Научно-исследовательский институт ревматологии им. В. А. Насоновой»РоссияV. A. Nasonova Research Institute of RheumatologyRussian Federation202625022026711-25663Copyright © Муравьева Н.В., Баранова М.М., Белов  Б.С., 20262026Муравьева Н.В., Баранова М.М., Белов  Б.С.Muravyeva N.V., Baranova M.M., Belov B.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/1330

У больных иммуновоспалительными ревматическими заболеваниями (ИВРЗ) риск развития пневмококковой инфекции выше, чем в общей популяции, что обусловлено аутоиммунным процессом и/или проводимой иммуносупрессивной терапией. Для профилактики указанной инфекции доступны 23-валентная пневмококковая полисахаридная вакцина (ППВ-23) и пневмококковые конъюгированные вакцины. ППВ-23 хорошо зарекомендовала себя в качестве безопасной и эффективной вакцины, что отражено в многочисленных работах отечественных и зарубежных авторов. В обзоре проанализированы исследования, касающиеся безопасности, иммуногенности и клинической эффективности пневмококковых конъюгированных вакцин.

Patients with autoimmune inflammatory rheumatic diseases (AIRDs) have a higher risk of developing pneumococcal infection than the general population due to an autoimmune process and/or ongoing immunosuppressive therapy. The 23-valent pneumococcal polysaccharide vaccine (PPV-23) and pneumococcal conjugate vaccines are available for the prevention of this infection. PPV-23 has proven itself to be a safe and effective vaccine, which is reflected in numerous studies by domestic and foreign authors. This review analyzes studies on the safety, immunogenicity, and clinical efficacy of pneumococcal conjugate vaccines.

иммуновоспалительные ревматические заболеванияпневмококковая инфекциявакцинация23-валентная пневмококковая полисахаридная вакцинапневмококковые конъюгированные вакцины7-валентная пневмококковая конъюгированная вакцина13-валентная пневмококковая конъюгированная вакцина20-валентная пневмококковая конъюгированная вакцинаautoimmune inflammatory rheumatic diseasespneumococcal infectionvaccination23-valent pneumococcal polysaccharide vaccinepneumococcal conjugate vaccines7-valent pneumococcal conjugate vaccine13-valent pneumococcal conjugate vaccine20-valent pneumococcal conjugate vaccineСтатья подготовлена в рамках научно-исследовательской работы ФГБНУ «Научно-исследовательский институт ревматологии им. В. А. Насоновой», № государственного задания РК 125020301268-4ReferencesО состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2024 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2025; 424.On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2024: State Report. Moscow: Federal Service for Supervision of Consumer Rights Protection and Human Welfare, 2025; 424. (in Russ.)].Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford). 2007; 46 (7): 1157–1160. doi: 10.1093/rheumatology/kem076.Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford). 2007; 46 (7): 1157–1160. doi: 10.1093/rheumatology/kem076.Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, et al. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Arthritis Rheumatol. 2016; 68 (1): 56–66. doi: 10.1002/art.39399.Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, et al. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Arthritis Rheumatol. 2016; 68 (1): 56–66. doi: 10.1002/art.39399.Mori S, Yoshitama T, Hidaka T, Sakai F, Hasegawa M, Hashiba Y, et al. Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. PLoS One. 2017; 12 (6): e0179179. doi: 10.1371/journal. pone.0179179.Mori S, Yoshitama T, Hidaka T, Sakai F, Hasegawa M, Hashiba Y, et al. Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. PLoS One. 2017; 12 (6): e0179179. doi: 10.1371/journal. pone.0179179.Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chanet KA. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008; 35 (3): 387–389.Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chanet KA. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008; 35 (3): 387–389.Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health. 2012; 66 (12): 1177–81. doi: 10.1136/jech-2011-200168.Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health. 2012; 66 (12): 1177–81. doi: 10.1136/jech-2011-200168.Белов Б.С., Буханова Д.В., Тарасова Г.М., Муравьева Н.В. Проблема инфекций нижних дыхательных путей в ревматологии: актуальность и пути решения. Эффективная фармакотерапия. 2020; 16 (6): 58–66. doi: https://doi.org/10.33978/2307-3586-2020-16-6-58-66Belov BS, Bukhanova DV, Tarasova GM, Muravyova NV. The Problem of lower respiratory tract infections in rheumatology: relevance and ways of solution. Effective Pharmacotherapy. 2020; 16 (6): 58–66. (in Russ.)]. doi: https://doi.org/10.33978/2307-3586-2020-16-6-58-66Koivuniemi R, Leirisalo-Repo M, Suomalainen R, Piirainen H, Paimela L. Infectious causes of death in patients with rheumatoid arthritis: an autopsy study. Scand J Rheumatol. 2006; 35 (4): 273–276. doi: 10.1080/03009740600556258.Koivuniemi R, Leirisalo-Repo M, Suomalainen R, Piirainen H, Paimela L. Infectious causes of death in patients with rheumatoid arthritis: an autopsy study. Scand J Rheumatol. 2006; 35 (4): 273–276. doi: 10.1080/03009740600556258.Rondaan C, Furer V, Heijstek MW, Agmon-Levin N, Bijl M, Breedveldet FC, et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open. 2019; 5: e001035. doi: 10.1136/rmdopen-2019-001035.Rondaan C, Furer V, Heijstek MW, Agmon-Levin N, Bijl M, Breedveldet FC, et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open. 2019; 5: e001035. doi: 10.1136/rmdopen-2019-001035.Белов Б.С., Муравьева Н.В., Баранова М.М., Тарасова Г.М., Сергеева М.С., Черкасова М.В. и др. Вакцинопрофилактика пневмококковой инфекции у больных ревматическими заболеваниями (по данным ФГБНУ НИИР им. В.А. Насоновой). Научно-практическая ревматология. 2025; 63 (4): 380–385. doi: https://doi.org/10.47360/1995-4484-2025-380-385.Belov BS, Muravyeva NV, Baranova MM, Tarasova GM, Sergeeva MS, Cherkasova MV, et al. Vaccination of pneumococcal infection in patients with rheumatic diseases (according to the V.A. Nasonova Research Institute of Rheumatology). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2025; 63 (4): 380– 385. (in Russ.)]. doi: https://doi.org/10.47360/1995-4484-2025-380-385.Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents. 2008; 32 (3): 199–206. doi: 10.1016/j.ijantimicag.2008.01.021.Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents. 2008; 32 (3): 199–206. doi: 10.1016/j.ijantimicag.2008.01.021.Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum 2011; 63: 3723–3732. doi: 10.1002/art.30580.Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum 2011; 63: 3723–3732. doi: 10.1002/art.30580.Kapetanovic MC, Saxne T, Jönsson G, Truedsson L, Geborek P. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013; 15: R171. doi: 10.1186/ar4358.Kapetanovic MC, Saxne T, Jönsson G, Truedsson L, Geborek P. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013; 15: R171. doi: 10.1186/ar4358.Grabar S, Groh M, Bahuaud M, Le Guern V, Costedoat-Chalumeau N, Mathian A, et al. Pneumococcal vaccination in patients with systemic lupus erythematosus: a multicenter placebo-controlled randomized doubleblind study. Vaccine. 2017; 35: 4877–4885. doi: 10.1016/j.vaccine.2017.07.094.Grabar S, Groh M, Bahuaud M, Le Guern V, Costedoat-Chalumeau N, Mathian A, et al. Pneumococcal vaccination in patients with systemic lupus erythematosus: a multicenter placebo-controlled randomized doubleblind study. Vaccine. 2017; 35: 4877–4885. doi: 10.1016/j.vaccine.2017.07.094.Kapetanovic MC, Roseman C, Jönsson G, Truedsson L. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs. Clin Rheumatol. 2011; 30: 1555–1561. doi: 10.1007/s10067-011-1856-5.Kapetanovic MC, Roseman C, Jönsson G, Truedsson L. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs. Clin Rheumatol. 2011; 30: 1555–1561. doi: 10.1007/s10067-011-1856-5.Nagel J, Geborek P, Saxne T, Jönsson G, Englund M, Petersson IF, et al. The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients. Arthritis Res Ther. 2015; 17 (1): 124. doi: 10.1186/s13075-015-0636-z.Nagel J, Geborek P, Saxne T, Jönsson G, Englund M, Petersson IF, et al. The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients. Arthritis Res Ther. 2015; 17 (1): 124. doi: 10.1186/s13075-015-0636-z.Nagel J, Jönsson G, Nilsson JÅ, Manuswin C, Englund M, Saxne T, Kapetanovic MC. Reduced risk of serious pneumococcal infections up to 10 years after a dose of pneumococcal conjugate vaccine in established arthritis. Vaccine. 2023; 41 (2): 504–510. doi: 10.1016/j.vaccine.2022.11.075.Nagel J, Jönsson G, Nilsson JÅ, Manuswin C, Englund M, Saxne T, Kapetanovic MC. Reduced risk of serious pneumococcal infections up to 10 years after a dose of pneumococcal conjugate vaccine in established arthritis. Vaccine. 2023; 41 (2): 504–510. doi: 10.1016/j.vaccine.2022.11.075.Kapetanovic MC, Saxne T, Truedsson L, Geborek P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther. 2013; 15 (1): R1. doi: 10.1186/ar4127.Kapetanovic MC, Saxne T, Truedsson L, Geborek P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther. 2013; 15 (1): R1. doi: 10.1186/ar4127.Rákóczi É, Perge B, Végh E, Csomor P, Pusztai A, Szamosi S, et al. Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept. Joint Bone Spine. 2016; 83: 675–679. doi: 10.1016/j.jbspin.2015.10.017.Rákóczi É, Perge B, Végh E, Csomor P, Pusztai A, Szamosi S, et al. Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept. Joint Bone Spine. 2016; 83: 675–679. doi: 10.1016/j.jbspin.2015.10.017.Nagel J, Saxne T, Geborek P, Bengtsson AA, Jacobsen S, Joergensen CS, et al. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine. Lupus. 2017; 26: 1072–1081. doi: 10.1177/0961203317695465.Nagel J, Saxne T, Geborek P, Bengtsson AA, Jacobsen S, Joergensen CS, et al. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine. Lupus. 2017; 26: 1072–1081. doi: 10.1177/0961203317695465.Nived P, Nagel J, Saxne T, Geborek P, Jönsson G, Skattum L, Kapetanovic MC. Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy. Vaccine. 2017; 35: 3639–3646. doi: 10.1016/j.vaccine.2017.05.044.Nived P, Nagel J, Saxne T, Geborek P, Jönsson G, Skattum L, Kapetanovic MC. Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy. Vaccine. 2017; 35: 3639–3646. doi: 10.1016/j.vaccine.2017.05.044.Nguyen MTT, Lindegaard H, Hendricks O, Jørgensen CS, Kantsø B, FriisMølleret N. Initial serological response after prime-boost pneumococcal vaccination in rheumatoid arthritis patients: Results of a randomized controlled trial. J Rheumatol. 2017; 44 (12): 1794–1803. doi: 10.3899/jrheum.161407.Nguyen MTT, Lindegaard H, Hendricks O, Jørgensen CS, Kantsø B, FriisMølleret N. Initial serological response after prime-boost pneumococcal vaccination in rheumatoid arthritis patients: Results of a randomized controlled trial. J Rheumatol. 2017; 44 (12): 1794–1803. doi: 10.3899/jrheum.161407.Caporuscio S, Ieraci R, Valesini G, Telonid R, Mariottid S, Spinellic FR, et al. Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy. Clin Immunol. 2018; 195: 18–27. doi: 10.1016/j.clim.2018.07.010.Caporuscio S, Ieraci R, Valesini G, Telonid R, Mariottid S, Spinellic FR, et al. Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy. Clin Immunol. 2018; 195: 18–27. doi: 10.1016/j.clim.2018.07.010.Winthrop KL, Bingham III CO, Komocsar WJ, Bradley J, Issa M, Klar R, Kartman CE. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. Arthritis Res Ther. 2019; 21: 102. doi: 10.1186/s13075-019-1883-1.Winthrop KL, Bingham III CO, Komocsar WJ, Bradley J, Issa M, Klar R, Kartman CE. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. Arthritis Res Ther. 2019; 21: 102. doi: 10.1186/s13075-019-1883-1.Winthrop KL, Vargas JI, Drescher E, Garcia C, Friedman A, Hendrickson B, et al. Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study. RMD Open. 2022; 8 (1): e002110. doi: 10.1136/rmdopen-2021-002110.Winthrop KL, Vargas JI, Drescher E, Garcia C, Friedman A, Hendrickson B, et al. Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study. RMD Open. 2022; 8 (1): e002110. doi: 10.1136/rmdopen-2021-002110.Lukina G, Murtazalieva D, Koltsova E, Kostinov M, Shmitko A, Blagovidov V, Zhilyaev E. Evaluation of the safety and efficacy of 13-valent pneumococcal vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2022; 81: S1: 1330. doi: 10.1136/annrheumdis-2022-eular.2530.Lukina G, Murtazalieva D, Koltsova E, Kostinov M, Shmitko A, Blagovidov V, Zhilyaev E. Evaluation of the safety and efficacy of 13-valent pneumococcal vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2022; 81: S1: 1330. doi: 10.1136/annrheumdis-2022-eular.2530.Mori S, Ueki Y, Ishiwada N. Impact of janus kinase inhibitors on antibody response to 13-valent pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Mod Rheumatol. 2023; 33 (2): 312–317. doi: 10.1093/mr/roac029.Mori S, Ueki Y, Ishiwada N. Impact of janus kinase inhibitors on antibody response to 13-valent pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Mod Rheumatol. 2023; 33 (2): 312–317. doi: 10.1093/mr/roac029.Муравьева Н.В., Баранова М.М., Белов Б.С. Безопасность и клиническая эффективность 13-валентной пневмококковой конъюгированной вакцины у больных иммуновоспалительными ревматическими заболеваниями (предварительные данные). В книге: Дни ревматологии в Санкт-Петербурге — 2025. Сборник тезисов XXV Юбилейного Всероссийского конгресса с международным участием. Санкт-Петербург, 2025; 162–163.Muravyeva NV, Baranova MM, Belov BS. Safety and clinical efficacy of 13-valent pneumococcal conjugate vaccine in patients with immuno-inflammatory rheumatic diseases (preliminary data). In the book: Rheumatology Days in St. Petersburg — 2025. Abstracts of the XXV Anniversary Russian Congress with international participation. St. Petersburg, 2025; 162–163. (in Russ.)].Kapetanovic MC, Nagel J, Nordström I, Saxne T, Geborek P, Rudin A. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine. 2017; 35: 903–908. doi: 10.1016/j.vaccine.2016.12.068.Kapetanovic MC, Nagel J, Nordström I, Saxne T, Geborek P, Rudin A. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine. 2017; 35: 903–908. doi: 10.1016/j.vaccine.2016.12.068.Bahuaud M, Beaudouin-Bazire C, Husson M, Molto A, Launay O, Batteux F, Dougados M. Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis. Hum Vaccin Immunother. 2018; 14: 1464–1470. doi: 10.1080/21645515.2018.1438091.Bahuaud M, Beaudouin-Bazire C, Husson M, Molto A, Launay O, Batteux F, Dougados M. Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis. Hum Vaccin Immunother. 2018; 14: 1464–1470. doi: 10.1080/21645515.2018.1438091.Salinas GF, De Rycke L, Barendregt B, Paramarta JE, Hreggvidstdottir H, Cantaert T, et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis. 2013; 72: 1037–1043. doi: 10.1136/annrheumdis-2011-201270.Salinas GF, De Rycke L, Barendregt B, Paramarta JE, Hreggvidstdottir H, Cantaert T, et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis. 2013; 72: 1037–1043. doi: 10.1136/annrheumdis-2011-201270.Morel J, Dernis E, Roux C, Richez C, Brocq O, Fautrel B, et al. Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial. Lancet Rheumatol. 2025; 7 (10): e675–e686. doi: 10.1016/S2665-9913(25)00071-2.Morel J, Dernis E, Roux C, Richez C, Brocq O, Fautrel B, et al. Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial. Lancet Rheumatol. 2025; 7 (10): e675–e686. doi: 10.1016/S2665-9913(25)00071-2.Жиляев Е.В., Лукина Г.В., Муртазалиева Д.А., Кольцова Е.Н., Шмидт Е.И., Лыткина К.А. и др. Влияние пневмококковой вакцинации на риск развития инфекционных осложнений у пациентов с ревматоидным артритом, получающих лечение таргетными противовоспалительными препаратами (данные Московского Единого Регистра Артритов (МЕРА)). Русский медицинский журнал. 2021; 29 (7): 7–12.Zhilyaev EV, Lukina GV, Murtazalieva DA, Koltsova EN, Shmidt EI, Lytkina KA, et al. The effect of pneumococcal vaccination on the risk of infectious complications in patients with rheumatoid arthritis treated with targeted anti-inflammatory drugs (data from the Moscow Unified Arthritis Registry (MUAR)). Russian Medical Journal. 2021; 29 (7): 7–12 (in Russ.)].Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, et al. Pivotal Phase 3 Randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged 18 years. Clin Infect Dis. 2021; 75 (3): 390–398. doi: 10.1093/cid/ciab990.Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, et al. Pivotal Phase 3 Randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged 18 years. Clin Infect Dis. 2021; 75 (3): 390–398. doi: 10.1093/cid/ciab990.Haranaka M, Song JY, Huang K-C, de Solom R, Yamaji M, McElwee K. A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults 60 years of age in Japan, South Korea, and Taiwan. Vaccine. 2024; 42 (5): 1071–1077. doi: 10.1016/j.vaccine.2024.01.004.Haranaka M, Song JY, Huang K-C, de Solom R, Yamaji M, McElwee K. A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults 60 years of age in Japan, South Korea, and Taiwan. Vaccine. 2024; 42 (5): 1071–1077. doi: 10.1016/j.vaccine.2024.01.004.Cannon K, Elder C, Young M, Scott DA, Scully IL, Baugher G. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults 65 years of age with different prior pneumococcal vaccination. Vaccine. 2021; 39 (51): 7494–7502. doi: 10.1016/j.vaccine.2021.10.032.Cannon K, Elder C, Young M, Scott DA, Scully IL, Baugher G. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults 65 years of age with different prior pneumococcal vaccination. Vaccine. 2021; 39 (51): 7494–7502. doi: 10.1016/j.vaccine.2021.10.032.Муравьев А.А., Чагарян А.Н., Иванчик Н.В., Миронов К.О., Гапонова И.И., Козлов Р.С. Эпидемиологическая характеристика серотипов Streptococcus pneumoniae, выделенных у пациентов с инвазивной пневмококковой инфекцией в Российской Федерации. Клиническая микробиология и антимикробная химиотерапия. 2025; 27 (2): 134–139. doi: https://doi.org/10.36488/cmac.2025.2.134-139.Muravyev AA, Chagaryan AN, Ivanchik NV, Mironov KO, Gaponova II, Kozlov RS. Epidemiological characteristic of Streptococcus pneumoniae serotypes from patients with invasive pneumococcal disease in the Russian Federation. Clinical Microbiology and Antimicrobial Chemotherapy. 2025; 7 (2): 134–139. (in Russ.)]. doi: https://doi.org/10.36488/cmac.2025.2.134-139.Furer V, Rondaan C, Heijstek M, van Assen S, Bijl M, Agmon-Levin N, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019; 5: e001041. doi: 10.1136/rmdopen-2019-001041.Furer V, Rondaan C, Heijstek M, van Assen S, Bijl M, Agmon-Levin N, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019; 5: e001041. doi: 10.1136/rmdopen-2019-001041.Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Johnson SR, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2023; 75(3): 333–348. doi: 10.1002/art.42386.Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Johnson SR, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2023; 75(3): 333–348. doi: 10.1002/art.42386.Инфекции и ревматические заболевания: руководство для врачей. Под ред. А.М.Лилы, Б.С.Белова. М.: ГЭОТАР-Медиа; 2024. doi: https://doi.org/10.33029/9704-8690-0-IRD-2024-1-184.Infections and rheumatic diseases: a guide for doctors. AM Lila, BS Belov. (eds.). Moscow: GEOTAR-Media; 2024. (in Russ)]. doi: https://doi.org/10.33029/9704-8690-0-IRD-2024-1-184.Белов Б.С., Муравьева Н.В. Вакцинопрофилактика инфекций и активность иммуновоспалительных ревматических заболеваний: pro et contra. Антибиотики и химиотер. 2024; 69 (1–2): 65–73. doi: https://doi.org/10.37489/0235-2990-2024-69-1-2-65-73.Belov BS, Muravyeva NV. Vaccinoprophylaxis of infections and activity of immunoinflammatory rheumatic diseases: pro et contra. Antibiotiki i Khimioter. = Antibiotics and Chemotherapy. 2024; 69 (1–2): 65–73 (in Russ)]. doi: https://doi.org/10.37489/0235-2990-2024-69-1-2-65-73.

The authors declare that there are no conflicts of interest present.